The initiation of this Network appeared to be a natural progression of the EUFEPS vision that biopharmaceutics forms the bedrock of many of the activities of the contributing societies. Its activities have provided many important opportunities to assist legislature in defining a harmonised approach across Europe. For example, proposed changes in European Guidelines in bioavailability and bioequivalence have prompted the scientific community to engage in a more comprehensive communication with regulatory scientists and to stimulate exchange between both groups.
EUFEPS/AAPS GLOBAL Bio Equivalence HARMONISATION INITIATIVE
The Global Bioequivalence Harmonisation Initiative is intended to support the process of global harmonization via scientific discussion among international stakeholders. Therefore, a series of international conferences was initiated by EUFEPS in collaboration with AAPS supported from the beginning by the European Medicines Agency (EMA) as well as the U.S. Food and Drug Administration (FDA).